Dr. Peter Martin, the Richard A. Stratton Associate Professor, Division of Hematology and Oncology, WDOM, and colleagues have published a pivotal paper in the Journal of Clinical Oncology. The paper, “Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts,” explores how treatment for mantle cell lymphoma can vary according to setting.
Involving a large cohort of patients, the study analyzed the use of autologous stem cell transplantation (ASCT) and found that the usage of ASCT (a type of bone marrow transplantation that uses a patient’s own cells) can be low in some patient settings. The study’s data supports the need to explore future clinical trials, as well as treatments for mantle cell lymphoma that can be delivered effectively in routine clinical practice.